AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01501032 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MD-logic artificial pancreas system
Description: The MD-logic artificial pancreas system is a closed loop control system using continuous glucose monitoring (CGM)and subcutaneous insulin pump infusion to mange glucose control in individuals with type 1 diabetes
Study NCT01362023 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle counseling
Description: In 3 academic years, the intervention program consisted of three components:~1. Classroom practice by HPA to highlight healthy lifestyle habits~2. Teaching practice by HPA using books designed to include the nutritional objectives~3. Parental activities included with their children~In each of 12 activities (1 h/activity), the classroom practice consisted of three components:~1. Experimental development of activities regarding each healthy lifestyle habit~2. Assessment of activity performed in classroom~3. An activity developed for use at home
Study NCT05430685 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ashwagandha
Description: Intervention and placebo group each received a bottle of 60 capsules. Subjects were instructed to take one capsule in the morning and 1 capsule in the evening. Intervention group was getting 350 mg ashwagandha root extract per capsule (or 700 mg per day). Each intervention capsule delivered 2.5 mg withanolides with equivalence of 2,700 mg dry herb.
Study NCT05430685 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The Placebo group received the same type of bottle with similar looking capsules. Each person in the placebo group was instructed to take 1 capsule twice a day (2 capsules total). Capsules were filled with glycerin to the same weight as ashwagandha. Capsules were indistinguishable from each other.
Study NCT01483456 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: The multidisciplinary prevention program called IPR (in French Identifier, Prévenir, Relever)
Description: The intervention is a multidisciplinary program of fall prevention including 3 complementary interventions which focus on several stages of elderly inpatient management:~1. Identification of patient's fall risk,~2. Multifactorial fall prevention program (integrated actions targeted on risk factors, exercise programs and review of the hospital environment),~3. Get up workshop and morbidity and mortality conferences related to fall cases
Study NCT04818723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: We wanted to know the role of leukotriene receptor antagonist (LTRA) montelukast in preventing relapses in idiopathic childhood nephrotic syndrome (NS)
Study NCT04818723 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Montelukast
Description: We wanted to know the role of leukotriene receptor antagonist (LTRA) montelukast in preventing relapses in idiopathic childhood nephrotic syndrome (NS)
Study NCT02510703 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Coronary endothelial function measurements by quantitative method (TEP at 15O-H2O)
Study NCT01768923 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SDAI remission
Description: SDAI remission group aims at the 2011 ACR/EILAR definition of remission (simplified disease activity score \[SDAI\] \<3.3)
Study NCT01768923 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimal disease activity remission
Description: Minimal disease activity group aims at minimal disease activity (DAS28\<2.6) (minimal disease activity group)
Study NCT00910117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nimotuzumab
Description: nimotuzumab 400 mg d1
Study NCT00910117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF regimen (cisplatin and 5-FU)
Description: cisplatin 75 mg/m2 d1 and 5-FU 750 mg/m2/d CIV d1-5
Study NCT03518398 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intense Pulsed Light
Description: E> Eye (E-SWIN, Paris, France) IPL machine
Study NCT03518398 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Standard treatment
Description: warm compression, lid scrub and non-preservative ocular lubricants
Study NCT03518398 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: Standard treatment
Description: warm compression, lid scrub and non-preservative ocular lubricants
Study NCT02061644 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Description: Routine spinal anesthesia procedure will be made to the patients for surgical anesthesia.
Study NCT01758042 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Haploidentical Bone Marrow/Kidney
Description: Combined bone marrow and kidney transplantation using a haploidentical donor.
Study NCT03884270 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnotherapy
Description: 7 sessions of self-administered gut-directed hypnotherapy for functional dyspepsia
Study NCT04100655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: 3ml GM-CSF gel will be irrigated into the uterine cavity immediately when hysteroscopy is complete. Then same dose gel will be given every other day twice
Study NCT04100655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 17-ß estradiol
Description: A hormone replace treatment by 17-ß estradiol (6mg per day) follows next cycle to prepare for embryo transfer
Study NCT01304290 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic/normoglycemic clamp
Description: Dextrose/insulin therapy will start. Dextrose and insulin are given using the so-called normoglycemic, hyperinsulinemic clamp. Plasma insulin concentration will be increased by a 2ìU/kg/min continuous infusion of insulin. Dextrose will be infused at the rate required to maintain normoglycemia (4-6 mmol/l) until cross clamping of the aorta. The dextrose/insulin therapy will be maintained for a time period of minimum 6 hours.
Study NCT01957839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabergoline treatment
Description: cabergoline treatment for hyperprolactinemia group
Study NCT02528617 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Velaglucerase alfa
Description: Enzyme replacement therapy
Study NCT03872817 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention ProLiSMentAl
Description: Using different methods and pedagogical techniques, mental health literacy psychoeducational intervention called ProLiSMentAl consist of 4 sessions of 90 minutes: 1) improvement social anxiety recognition; 2) prevention strategies; 3) self-help strategies; 4) knowledge of first aid strategies and 5) knowledge of professionals and treatments available.
Study NCT04063995 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation
Description: Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive intervention that uses magnetic fields to stimulate nerve cells to improve the symptoms of a variety of disorders, including stroke-related motor impairment.
Study NCT04063995 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation
Description: Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive intervention that uses magnetic fields to stimulate nerve cells to improve the symptoms of a variety of disorders, including stroke-related motor impairment.
Study NCT02474355 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: T790M+ Testing
Description: If a previous lab report is unavailable, the patient will need to have T790M+ testing.
Study NCT02474355 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Baseline Visit Blood & Urine Testing
Description: Blood count and standard chemistry testing to ensure patient meets inclusion/exclusion criteria
Study NCT02474355 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Baseline ECG
Description: ECG to ensure absence of any cardiac abnormality
Study NCT02474355 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Visual Slit-Lamp Testing
Description: Slit-lamp testing performed to ensure patients do not have any eye abnormalities or symptoms
Study NCT02474355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9291 Dosing
Description: Patients to be provided with AZD9291 every 6 weeks (+/- 7 days)
Study NCT03685500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symtuza® (TAF/FTC/DRV/c)
Description: Treatment with TAF/FTC/DRV/c during 8 weeks since randomized
Study NCT03685500 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABC/3TC/DTG + Symtuza® (TAF/FTC/DRV/c)
Description: Patients continuing on treatment with DTG/3TC/ABC after the randomization for 4 weeks, and then switch to TAF/FTC/DRV/c for 8 weeks
Study NCT04605926 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EQ001
Description: itolizumab \[Bmab600\]
Study NCT04605926 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: EQ001 Placebo
Description: EQ001 Placebo
Study NCT04688606 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Circulating tumor cell capture technology
Description: CTCBIOPSY® automatic testing platform
Study NCT01859871 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Website Intervention
Description: Study participants will take the self-administered pre-test in the intervention arm and will be introduced to the website to inform the public of various topics concerning end-stage kidney disease and kidney transplantation. Few websites about transplantation are tailored to potential Hispanic kidney transplant candidates or the Hispanic community. This website is designed to fill the void and be an effective bilingual web-based educational resource targeted to Hispanic patients and public which can serve as a culturally competent tool to enhance knowledge and attitudes about living kidney donation.
Study NCT01601067 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Prolonged Exposure Therapy
Description: Prolonged exposure (PE) therapy is an evidence based practice for the treatment of PTSD. Components of PE included education about PTSD and exposure to avoided reminders of trauma.
Study NCT01601067 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Seeking Safety
Description: Seeking Safety (SS) teaching coping skills in behavioral, cognitive, and interpersonal domains so that people are able to make safe choices rather than drinking or PTSD-related behaviors such as avoidance.
Study NCT00525876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Matched Donors:~750 mg/m\^2 given intravenously on Day -3, 4 hours after completion of Fludarabine.~Unrelated or Mismatched Donors:~1000 mg/m\^2 given intravenously on Day -3, 4 hours after completion of Fludarabine.~(Stem Cell Transplantation and Low Dose Total Body Irradiation = Day 0)
Study NCT00525876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2 given intravenously on Days -5 and -3 before transplantation.~(Stem Cell Transplantation and Low Dose Total Body Irradiation = Day 0)
Study NCT00525876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Matched Donors:~375 mg/m\^2 given intravenously on Days -13, -6 before transplantation and Days 16, 8 after transplantation.~Unrelated/Mismatched Donors:~375 mg/m\^2 given intravenously on Days -8, -1 before transplantation and Days 6, 13 after transplantation.~(Stem Cell Transplantation and Low Dose Total Body Irradiation = Day 0)~For development of disease progression or no response, immunomanipulation with Rituximab 375 mg/m\^2 given intravenously, then 1000 mg/m\^2 given intravenously weekly for 3 weeks, and taper off Tacrolimus dose over 2 weeks.~DLI = Donor Lymphocyte Infusion/Immunomodulation Post Transplantation Immunomodulation for patients with lymphoid Malignancies:~375 mg/m\^2 then 1000 mg/m\^2 weekly x 3 if immunomanipulation is undertaken for persistent disease.
Study NCT00525876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Unrelated/Mismatched Donors:~15 mg per day given intravenously days 1 through 3 after transplantation.~(Stem Cell Transplantation and Low Dose Total Body Irradiation = Day 0)
Study NCT00525876 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Stem Cell Infusion
Description: Infusion of stem cells.
Study NCT00596453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin hydrochloride
Description: 250 mg Ciprofloxacin hydrochloride twice a day for 14 days
Study NCT00596453 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo twice a day for 14 days
Study NCT01527708 — intervention group
Intervention type: PROCEDURE
Intervention: Corneal Collagen Cross-linking (CXL)
Description: Instillation of proparacaine hydrochloride 0.5% drops for topical anaesthesia, application of a sponge saturated with 10% alcohol to the central cornea for 20-30 seconds and subsequent de-epithelialization by means of a hockey knife. Following de-epithelialization, a mixture of 0.1% riboflavin in 20% Dextran solution was instilled to the cornea for 30 minutes (2 drops every 2 minutes) prior to the irradiation. In details, an 8.0mm diameter of central cornea was irradiated for 30 minutes by UVA light with a wavelength of 370nm and an irradiance of 3mW/cm2.The UVA radiation source that was used is the UV-XTM (IROC AG, Zurich, Switzerland). Instillation of riboflavin drops (1 drop every 2 minutes) was continued during irradiation, as well.
Study NCT03310892 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Generic message
Description: Generic message
Study NCT03310892 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored message
Description: Tailored message
Study NCT04104997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% GLH8NDE
Description: 5% GLH8NDE as eye drops
Study NCT00521859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cloretazine
Description: 800 mg/m\^2 by vein daily
Study NCT00521859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m\^2 by vein daily x 5 Days
Study NCT04104997 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo as eye drops
Study NCT04468815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986278 Tablet
Description: Specified dose on specified days
Study NCT04468815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Specified dose on specified days
Study NCT04468815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986278 suspension
Description: Specified dose on specified days
Study NCT00533559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium phenylbutyrate
Description: buphenyl, 7.5 gm/day for two weeks for two studies, one with saline and one admission with intralipid and heparin
Study NCT00533559 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study NCT04229056 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-based cognitive rehabilitation (CBCR)
Description: CBCR are software-programmes for computers which are clinically developed for rehabilitation of various cognitive functions.
Study NCT04229056 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General computer-based cognitive stimulation
Description: For this trial we have developed a webpage for cognitive sham-training, which is designed to provide general computer-based cognitive stimulation.
Study NCT02217800 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: saline
Description: Eligible patients are to receive a constant 23 hour subcutaneous infusion of saline as placebo comparator and will be randomized in an equal ratio to one of three treatment sequences of doses of 920, 2760 and 5520 µg DG3173 by constant 23 hour subcutaneous infusions in a random sequence followed by three subcutaneous injections of 300 µg octreotide at approximately 8 hour intervals as an active comparator.
Study NCT02217800 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: DG3173
Description: Eligible patients are to receive a constant 23 hour subcutaneous infusion of saline as placebo comparator and will be randomized in an equal ratio to one of three treatment sequences of doses of 920, 2760 and 5520 µg DG3173 by constant 23 hour subcutaneous infusions in a random sequence followed by three subcutaneous injections of 300 µg octreotide at approximately 8 hour intervals as an active comparator.
Study NCT02217800 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: octreotide
Description: Eligible patients are to receive a constant 23 hour subcutaneous infusion of saline as placebo comparator and will be randomized in an equal ratio to one of three treatment sequences of doses of 920, 2760 and 5520 µg DG3173 by constant 23 hour subcutaneous infusions in a random sequence followed by three subcutaneous injections of 300 µg octreotide at approximately 8 hour intervals as an active comparator.
Study NCT01752010 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Chinese Acupuncture
Description: Treatment will be performed by an experienced provider, and may include insertion of sterile 32-gage (0.25mm) acupuncture needles on any part of the body that can be needled while the subject is lying prone with their head in a face cradle. The needles are usually retained for 20-30 minutes along various meridian points identified by the practitioner as being blocked. Needles will be inserted to the depth typically recommended for the particular point of concern; generally 1 to 3cm. There are no constraints on the number of needles used. Acupuncture points are points of lower resistance and higher electrical conductance than the surrounding tissue. Placing the acupuncture needles into points identified as blocked is believed to help restore the flow of energy and stimulates the release of endorphins. The subject's level of pain is assessed on a 0-10 pain scale. Thirty minute acupuncture treatments will be given by the provider once a week for 6 weeks at the pain clinic.
Study NCT01752010 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tennant™ Biomodulator Treatment
Description: An FDA-approved Tennant™ 650 BioModulator will be used to deliver electrical stimulation. The device will be applied directly on top of the subject's area of pain for one minute; power is adjusted until the subject feels a slight tingle. Random variations of pulse amplitude are set from zero to a chosen comfort limit. A feedback mechanism is provided by the constant monitoring of skin impedance. The device is then pressed onto the site of pain and rotated counter-clockwise. After a minute, the device is placed on the opposite side of the pain site and the procedure repeated. The subject's level of pain is assessed on a 0-10 pain scale. At no time is the level of electrical stimulation allowed to cause sustained pain. The subject will receive a weekly 15 minute visit that includes a treatment provided by the pain provider. The provider will teach the subject how to use the machine by themselves and instruct the subject to use the machine twice a day on their own during the study.
Study NCT01752010 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS) Treatment
Description: An FDA-approved Empi™ TENS unit will be used to deliver the transcutaneous electrical nerve stimulation. The low frequency TENS unit will be applied to the subject's area of pain by the use of four integrated self-adhering 5x5 cm electrodes. The electrodes will be positioned at a distance of 3 cm and centered over the area that is most painful. The device rapidly delivers therapeutic electrical currents at various frequencies off and on 150 times a second. The subject's level of pain is assessed on a 0-10 pain scale. At no time is the level of electrical stimulation allowed to cause sustained pain. The subject will receive a weekly 15 minute visit that includes a treatment provided by the pain provider. The provider will teach the subject how to use the machine by themselves and instruct the subject to use the machine twice a day on their own during the study.
Study NCT03750526 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: rTMS and AR
Description: rTMS performs 1Hz,15 minutes real rTMS. AR intervention contains weight-shift exercise, strengthening of lower limb and balance training for 45 minutes.
Study NCT03750526 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sham rTMS and AR
Description: Sham rTMS applies 1Hz, 15 minutes sham rTMS. AR intervention includes weight-shift exercise, strengthening of lower limb and balance training for 45 minutes.
Study NCT03750526 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: AR
Description: AR intervention contains weight-shift exercise, strengthening of lower limb and balance training for 60 minutes.
Study NCT03750526 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Description: Conventional physiotherapy includes rolling, sitting, balance exercise, standing, overground walking, facilitation of the paretic limbs, and so on for 60 minutes.
Study NCT01633476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valaciclovir
Description: 2g q.d.s. orally for 6 months (dose adjusted according to renal function)
Study NCT00912145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam Tablets, 2 mg (Geneva Pharmaceuticals, Inc.)
Study NCT00912145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alprazolam Tablets, 2 mg (Geneva Pharmaceuticals, Inc.)
Study NCT00554645 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multi-disciplinary group intervention
Description: children:weekley session in 6 months, monthly sessions for 6 months parents: bi-monthly sessions for 6 months, monthly sessions for 6 months